Revolutionizing Genetic Editing: The Role of Recombinant AICDA

Recombinant Human Single-stranded DNA Cytosine Deaminase

Recombinant Human Single-stranded DNA Cytosine Deaminase (AICDA) is an enzyme synthesized through genetic engineering techniques. It catalyzes the conversion of cytosine to uracil in single-stranded DNA molecules, playing a crucial role in processes like antibody diversification and DNA repair.



AICDA-based technologies can be scaled up for industrial or clinical applications, offering scalability and feasibility for large-scale DNA editing and therapeutic interventions.


Recombinant versions of AICDA can be produced with stringent quality control measures, ensuring purity and minimizing potential risks associated with off-target effects or unintended genetic modifications.


AICDA can be combined with other molecular tools or enzymes to create complex genetic circuits or multiplexed editing systems, allowing for sophisticated manipulation of DNA sequences.


Research Tools

AICDA is used as a research tool to induce targeted mutagenesis in DNA sequences. By introducing specific mutations, researchers can study gene function, protein structure, and disease mechanisms.

Gene Therapy

AICDA has potential applications in gene editing and gene therapy. It can be used to induce targeted DNA modifications for therapeutic purposes, such as correcting genetic mutations or regulating gene expression.

Cancer Immunotherapy

AICDA-mediated DNA editing can enhance the efficacy of cancer immunotherapy by increasing the immunogenicity of tumor cells. This approach may help stimulate anti-tumor immune responses and improve treatment outcomes.

Your Dynamic Snippet will be displayed here... This message is displayed because you did not provided both a filter and a template to use.

Advancing Alzheimer's Disease Research with Amyloid Beta AffiREC: A Revolutionary Antibody Technology